These findings highlight STAT3 signaling as a deleterious pathway supporting the protumoral activity of neutrophils and suggest that neutrophil-targeted STAT3 inhibition is a promising opportunity for cancer immunotherapy, providing novel insights into targeted therapeutic avenues. The gene discussed is STAT3; the disease is cancer.